|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||57.09 - 58.01|
|52 Week Range||43.51 - 72.41|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||61.67|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.67|
SAN DIEGO, June 17, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the commercial launch of Modulus® TLIF-O, a porous titanium spine implant engineered for the transforaminal lumbar interbody fusion (TLIF) procedure. This further expands the application of the Company's Advanced Materials Science™ (AMS) portfolio to more of its procedural offerings and the most commonly performed procedure in the spine industry. Modulus TLIF-O features porous surface technology that, based on pre-clinical data, provides a favorable environment for bone in-growth and bone on-growth, and consistently achieves stronger osseointegration than solid implants with smooth or rough surfaces.1-4 The porous and roughened endplate design promotes new bone on-growth at four weeks and demonstrates the greatest integration strength by 12 weeks compared to alternative implant materials.5 Modulus TLIF-O's lattice structure is optimized for each implant size through NuVasive's proprietary algorithm that balances strength and radiolucency, while also mimicking the stiffness of bone.5 This optimized lattice structure enables enhanced imaging for visualization of spinal fusion compared to solid titanium interbody implants.
SAN DIEGO, June 12, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its LessRay® radiation reduction and workflow enhancement platform was voted a gold winner in the Radiological, Imaging and Electromechanical Devices category at the 2019 Medical Design Excellence Awards (MDEA) held in New York City on June 11, 2019. The LessRay platform is built on a proprietary algorithm that captures and enhances low-dose, low-quality images to produce images with similar diagnostic capabilities as conventional full-dose images. This technology has the ability to reduce radiation emissions to the operating room (OR) staff and patient by 75 percent compared to standard fluoroscopy.1 Additionally, LessRay contains a number of surgical efficiency features designed to save time during spine surgery, which can decrease time under anesthesia for the patient.
NuVasive Inc NASDAQ/NGS:NUVAView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for NUVA with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 28. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $118 million over the last one-month into ETFs that hold NUVA are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SAN DIEGO, May 30, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions announced today that the Company's SpineTRACK Registry submitted successful quality performance data to the Centers of Medicare & Medicaid Services (CMS) on behalf of healthcare providers at Southern Oregon Neurosurgical & Spine Associates (SONSA) for the Merit-based Incentive Payment System (MIPS). As a result, SONSA providers are eligible for a positive adjustment of up to seven percent on all Medicare reimbursements for the 2020 payment year.
SAN DIEGO, May 14, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company continues its commitment to the Society of Lateral Access Surgery (SOLAS) as a Global Partner, the leading sponsorship level in the partnership program, at the 12th annual SOLAS meeting being held May 16-18, 2019 in Miami, Florida. NuVasive will also participate in exhibit and workshop programs, featuring its comprehensive approach to lateral single-position surgery with the X360™ system integrated with Surgical Intelligence™. During the meeting, NuVasive will host a lunch symposia, X360 powered by Surgical Intelligence, presented by Brett Braly, MD, and Brian Kwon, MD, on May 17, 2019 from 12:45 to 2:15 p.m. ET.
A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. NuVasive, Inc. (NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching NuVasive, Inc. (NASDAQ:NUVA) might want to consider the historical volatility of t...
NuVasive (NUVA) delivered earnings and revenue surprises of 29.27% and 2.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had net income of 18 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 53 cents per share. The results surpassed Wall Street ...
SAN DIEGO , May 1, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated ...
On Wednesday, May 1, NuVasive (NASDAQ: NUVA ) will release its latest earnings report. Check out Benzinga's preview to understand the implications. Earnings and Revenue NuVasive earnings will be near 41 ...
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost more than 25%. Facebook, which was the second most popular stock, lost 20% amid uncertainty regarding the interest rates and tech […]
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.